LGR6 and breast carcinoma: Consistent with the published results in the NHGRI-EBI catalog, a total of 16, 15, and 18 genes above aGWS in CGEM, EPIC, and PBCS, respectively, are involved in the three known disease pathways, such as membrane-associated receptor signaling (G protein–coupled receptors [GPCR], Fc receptors [FcR], hemagglutinin [HA], receptor tyrosine kinases [RTK], or ion channels), MAP kinases, and in nuclear proteins involved in cell cycle control, transcription, or splicing in breast cancer (Table 1).